Ulipristal acetate: An update for Australian GPs

Aust Fam Physician. 2017;46(5):301-304.

Abstract

Background: In Australia, use and understanding of emergency contraception among women remains relatively low. This is despite the introduction of levonorgestrel emergency contraceptive pills (ECPs) more than a decade ago. In April 2016, a new ECP with the active ingredient ulipristal acetate became available in Australia.

Objective: The aims of this article are to increase understanding of the recently introduced ulipristal acetate ECP, including its safety profile, effi-cacy and special considerations; dispel common myths and misconceptions about emergency contraception; and to provide guidance on emergency contraceptive management in general practice, considering the recent advances.

Discussion: Women are more receptive to information about emergency contraception that has been provided by a general practitioner (GP). As such, the availability of the ulipristal acetate ECP in Australia provides an important opportunity for GPs to help women prevent unplanned pregnancies.

MeSH terms

  • Adult
  • Australia
  • Contraception, Postcoital / methods*
  • Contraceptives, Oral, Hormonal / pharmacology
  • Contraceptives, Oral, Hormonal / therapeutic use
  • Female
  • General Practitioners / trends*
  • Humans
  • Norpregnadienes / adverse effects
  • Norpregnadienes / pharmacology*
  • Norpregnadienes / therapeutic use
  • Obesity / complications
  • Overweight / complications
  • Pregnancy
  • Pregnancy, Unplanned
  • Primary Health Care / methods

Substances

  • Contraceptives, Oral, Hormonal
  • Norpregnadienes
  • ulipristal acetate